HRTX Q2 2018 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$17M+103.0% YoY

Gross Profit

$12M69.7% margin

Operating Income

-$39M-224.9% margin

Net Income

-$39M-223.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+49.4%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$62M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$511M

Total Liabilities

$79M

Stockholders' Equity

$432M

Cash & Equivalents

$259M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$17M	$9M	+103.0%
Gross Profit	$12M	$7M	+60.7%
Operating Income	-$39M	-$42M	+7.6%
Net Income	-$39M	-$43M	+9.6%